At the start, pembrolizumab is given over a period of time, with regular medical checks during treatment. After treatment, the cancer is checked again with tests such as a CT scan, which is a special X-ray picture of the body, and an endoscopy, which is a thin tube test used to look inside the bowel. Based on these results, some people may go on to surgery, while others may be monitored closely without immediate surgery. The study also follows health over time to learn about possible side effects, recovery, and general well-being.

Participants in the study will be assigned to receive either the active medication HRX215 taken as an oral capsule or a placebo. The study is designed so that neither the participants nor the researchers know which substance is being administered. During the course of the study, the way the body absorbs, processes, and removes the medication will be monitored and compared to data from healthy individuals.

The research also involves looking at how the liver recovers after surgery. This includes monitoring changes in liver volume, which is the amount of space the liver occupies in the body, using computed tomography, a type of medical imaging that uses X-rays to create detailed pictures of the inside of the body. General health indicators, such as vital signs and blood tests, will also be tracked to ensure patient safety.

The main purpose of this research is to determine if patients who receive lidocaine during their colon cancer surgery need less pain medication (specifically opioid medications) in the first 24 hours after their operation. The study will also look at how quickly patients regain normal bowel function after surgery.

During the study, patients will receive either lidocaine or a sodium chloride solution (standard salt water) through an intravenous line. The treatment will be given during the surgical procedure and continue for a short time afterward. The amount of pain medication needed and the time until normal bowel function returns will be monitored after the surgery.

The purpose of this study is to observe the changes in the body at a molecular level when patients with untreated colon cancer receive Dostarlimab before surgery. This approach is known as neoadjuvant therapy, which means the treatment is given to shrink the tumor before it is surgically removed. The study will help create a database of these changes, which can be used for future research. Participants will receive Dostarlimab and will be monitored for any changes in their condition, as well as for any side effects that may occur during the treatment period.

The study will also look at how well patients respond to the treatment and how it affects their overall survival. This includes tracking the time from the start of the study to any recurrence of cancer or death. The safety of Dostarlimab will be closely monitored, including any adverse effects that might lead to stopping the treatment or affect the patient’s ability to undergo surgery. The study aims to provide valuable information on the effectiveness and safety of Dostarlimab as a treatment option for this type of colon cancer.

The treatments being studied include several medications: Elvorine (levoleucovorin), Xeloda (capecitabine), Folinic acid (as calcium folinate), and Fluorouracil. Elvorine is given as an injection, Xeloda is taken as a tablet, and both Folinic acid and Fluorouracil are administered through an injection or infusion. These medications are used in combination with chemotherapy to help prevent the cancer from returning.

Participants in the study will receive one of the treatment strategies and will be monitored over a period of time to assess their health and any side effects. The study will also look at how well patients tolerate the treatments, how long it takes for the cancer to return, and the overall survival of the patients. Additionally, the study will consider the impact of the treatments on the patients’ quality of life and independence. The trial is expected to continue until August 2025.

The purpose of the study is to determine if this treatment approach, which includes chemotherapy before surgery, followed by surgery and additional chemotherapy, can improve the time patients remain free from cancer after surgery, compared to the standard treatment of surgery followed by chemotherapy. The study will follow participants over a period of time to see if this new approach helps them stay cancer-free for longer.

Participants in the study will receive the treatment over a period of several months. The study will monitor their health and progress, looking at how well the treatment works and any side effects that may occur. The goal is to see if this new treatment plan can help improve outcomes for people with locally advanced colon cancer.

The purpose of the study is to evaluate how well this treatment strategy works over a period of time. Participants in the study will receive pembrolizumab, which is given as an infusion directly into the bloodstream. The study will also involve other medications, including capecitabine, oxaliplatin, and fluorouracil, which are commonly used in cancer treatment. These medications may be given in different combinations depending on the specific needs of the patient. The trial will monitor the success of the treatment strategy at various points, such as 6 months and 24 months after starting the treatment.

Throughout the study, participants will undergo regular check-ups and tests to assess their response to the treatment. This includes imaging tests like computed tomography (CT) scans to evaluate the size and spread of the cancer. The study aims to determine the safety and effectiveness of the treatment strategy, as well as its impact on the quality of life for participants. The trial will also track any side effects and overall survival rates to provide a comprehensive understanding of the treatment’s benefits and risks.

Participants in the study will receive the chemotherapy drug oxaliplatin through a method known as intraperitoneal use, meaning it is administered directly into the abdominal area. The study will involve two treatments with PIPAC, and researchers will monitor patients over time to check for any recurrence of cancer using imaging techniques like computed tomography (CT) scans. The study will also look at the safety of the treatment and any side effects that may occur.

The trial aims to follow patients for several years to gather information on how well the treatment works in preventing the return of cancer and to assess overall survival rates. This research could provide valuable insights into new ways to manage high-risk colon cancer after surgery.

The purpose of this study is to see how well the combination of and works in reducing the size of the tumor in patients with this specific type of cancer. The study will involve patients receiving these treatments over a period of time, and their progress will be monitored through various medical assessments. Some patients may receive a as part of the study to help compare the effects of the actual treatment. The study aims to gather information on the safety of the treatment, how long patients live after treatment, and how the cancer responds to the treatment.

Participants in the study will undergo regular check-ups and imaging tests to track the changes in their cancer. The study will also look at the overall quality of life of the participants during and after the treatment. The results of this study could provide valuable insights into the effectiveness of using and together for treating .

The purpose of the study is to see if this combination of drugs can help patients who have a specific marker in their blood, called circulating tumor DNA (ctDNA), which indicates a higher risk of cancer returning. The study will compare the outcomes of patients who receive the FOLFOX6m treatment with those who do not, to determine if the treatment is effective in preventing the cancer from coming back.

Participants in the study will receive the treatment over a period of six months. During this time, they will be monitored regularly to check their health and see how well the treatment is working. The study will also look at how long it takes for the cancer to return, if it does, and the overall survival of the patients. The trial is expected to continue until March 2026, with the goal of improving the long-term health of patients with stage II colon cancer.

The main purpose of this research is to determine how well this imaging method can find cancer that has spread to lymph nodes near the colon. During the study, participants will receive a single injection of [18F]FAPI-74 before having the PET/CT scan. The amount of radioactive substance used will not exceed 400 megabecquerels (a unit used to measure radioactivity).

The study will look at different groups of patients: those who have newly diagnosed colon cancer with possible spread to nearby lymph nodes, those who have colon cancer that might be curable despite having spread, and those who are being monitored after previous treatment with suspected return of cancer. The imaging results will help doctors better understand how well this new technique works for detecting the spread of colon cancer.

Participants in the study will be randomly assigned to receive either aspirin or a placebo. The aspirin used in this study is a 100 mg dose in the form of a gastro-resistant tablet, which means it is designed to dissolve in the intestine rather than the stomach. This helps to reduce stomach irritation. The study will last for a period of up to 36 months, during which participants will take the medication orally.

The trial aims to assess the disease-free survival rate, which refers to the length of time after treatment during which the patient remains free of cancer. Additionally, the study will monitor overall survival rates and any side effects, such as severe bleeding or other adverse events. The results will help determine if aspirin is effective in improving outcomes for patients with this type of colon cancer.

The treatment involves different combinations of chemotherapy medications including oxaliplatin, fluorouracil, capecitabine, and levoleucovorin. These medications are given either as tablets taken by mouth or as solutions administered through a vein. The chemotherapy combinations used in this study are known as CAPOX and FOLFOX.

The treatment period lasts up to 6 months, during which patients receive regular doses of chemotherapy medications. Throughout the study, patients will need to undergo various medical examinations and tests to monitor their health and response to treatment. The success of the treatment will be measured by how many patients can complete the entire planned treatment sequence.

The purpose of the study is to investigate how effective this chemotherapy is in improving the time patients remain free from the disease after treatment. Participants in the study will receive either the neoadjuvant chemotherapy or the standard treatment for colon cancer. The study will last for a period of up to 24 months, during which the effects of the treatment will be monitored and compared.

By participating in this study, researchers aim to gather information on whether the neoadjuvant chemotherapy can help improve outcomes for patients with locally advanced colon cancer. The ultimate goal is to determine if this approach can lead to better long-term results for patients by increasing the time they remain free from cancer after treatment.

The study compares two groups of patients – one receiving Peginterferon alfa-2a and another receiving placebo. The treatment involves giving the medication at specific doses before and after the surgical procedure. During the study, patients will receive either the study medication or placebo for up to 14 days. The study also includes the use of sodium chloride solution as part of the treatment.

The main purpose of this research is to understand how this medication affects certain immune cells in the body and within the tumor tissue during the surgical period. The study will examine how the immune system responds to the treatment by looking at different types of immune cells in both the blood and the removed tumor tissue.

The purpose of the study is to determine the safety and feasibility of using these treatments before surgery in patients with colon cancer. The study will involve administering these medications over a period of time before the planned surgery. Participants will receive either the study medications or a placebo. The trial aims to see how well the treatments work in reducing the size of the tumor and improving the chances of a successful surgery.

Throughout the study, participants will be closely monitored to assess the effects of the treatments. This includes regular check-ups and tests to ensure the safety of the participants and to gather information on how the treatments are affecting the cancer. The study will also look at how the immune system responds to the treatments, as well as any changes in the tumor itself. The ultimate goal is to find effective treatment combinations that can improve outcomes for patients with early-stage colon cancer.

The purpose of the study is to determine if taking aspirin regularly after standard cancer treatment can help prevent the cancer from coming back and improve the chances of survival. Participants in the study will be randomly assigned to receive either the aspirin or the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the aspirin and who is receiving the placebo. This helps ensure that the results are not influenced by expectations or bias.

Participants will take the study medication for a period of up to 60 months. Throughout the study, participants will be monitored for any side effects and for signs of cancer recurrence. The study will also look at other health outcomes, such as overall survival, adherence to the medication, and any serious health events that may occur. The goal is to gather information that could lead to better treatment strategies for preventing cancer recurrence and improving survival rates in patients with these types of cancers.

The purpose of this study is to provide access to selpercatinib for patients who have these advanced cancers with the RET gene change. The study is designed to help patients who are not eligible for other ongoing clinical trials of selpercatinib. Participants will take the medication over a period of time, and their health will be monitored by their healthcare team. The study does not involve any specific data analysis or endpoints, meaning it is primarily focused on providing the treatment rather than collecting data for research purposes.

Patients who participate in this study will receive selpercatinib as part of an expanded access program, which is a way to provide treatment to patients who have no other options available. The treatment period can last up to 84 days, and the medication is taken orally. This study aims to support patients with advanced cancers by offering them a potential treatment option when other therapies are not suitable or available.

Participants in the trial will receive one of the following treatments: FOLINIC ACID, FLUOROURACIL, IRINOTECAN, or a combination of TRIFLURIDINE and TIPIRACIL (known as Lonsurf). These medications are commonly used in chemotherapy and will be administered in various forms, such as injections or tablets. Some participants may receive a placebo instead of active treatment. The study will compare the time it takes for the cancer to return in patients receiving these treatments versus those under regular observation.

The trial will last for a period of up to six months, during which patients will be closely monitored. The main goal is to determine the time to recurrence of the disease, while secondary goals include overall survival, disease-free survival, and the time it takes for ctDNA to become undetectable. The study also aims to evaluate the tolerability of the treatments and their impact on the quality of life of the participants. This research is important for understanding how to better manage colorectal cancer in patients who are at risk of recurrence after initial treatment.

The purpose of this study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive the combination of these medications and will be monitored for any side effects and how their cancer responds to the treatment. The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The study aims to understand how well the combination of these medications can help in treating the different types of cancer mentioned.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers learn more about the potential benefits and risks of using Pembrolizumab, Lenvatinib, and Belzutifan together, which could lead to new treatment options for patients with these types of cancer in the future.

The purpose of the study is to determine if this new imaging method is safe and can be effectively used in patients. During the study, participants will undergo a procedure where the capsule is swallowed and then manually retrieved, capturing high-resolution images of the digestive tract. This imaging technique combines structural imaging with a special type of imaging called near-infrared fluorescence, which helps visualize specific areas of interest, such as potential tumor sites or areas of inflammation.

The study will monitor the safety of the immuno-OCT imaging by tracking any device-related side effects. It will also assess how well the imaging method works in practice. The results from this imaging will be compared to other imaging techniques and tissue analysis to validate its effectiveness. The study is expected to continue until early 2025, with recruitment starting in December 2023.

The purpose of this study is to see how well this combination of treatments works when given before surgery to remove the cancer. The study will involve patients receiving these treatments over a period of time before they undergo surgery. During the study, some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study aims to understand if this combination can improve the response of the cancer to treatment before surgery.

Participants in the study will receive the treatments in a controlled setting, and their health will be monitored closely by medical professionals. The study will help researchers learn more about the potential benefits and any side effects of using Ipilimumab, Nivolumab, and high-dose Vitamin C together in treating this type of colon cancer. This research is important for developing new ways to treat cancer and improve outcomes for patients.

The purpose of this research is to compare two different chemotherapy combinations – one called mFOLFIRINOX (which includes all four medications) and another called mFOLFOX (which includes all medications except irinotecan). Both treatments are given to patients after they have had surgery to remove their cancer, which is known as adjuvant treatment. The study aims to determine which combination is more effective at preventing the cancer from returning.

During the study, patients will receive their assigned treatment through an intravenous line (a thin tube inserted into a vein). The medications will be given in specific doses calculated based on each patient’s body size. The treatment will be administered in cycles, with regular check-ups to monitor how well the treatment is working and to watch for any side effects.

The purpose of the study is to understand how a genetic test, called the DPYD gene test, can affect the safety and effectiveness of these cancer treatments. The study will explore whether this test can help identify genetic differences that might influence how well the treatments work and how safe they are for individual patients.

Participants in the study will receive one of the medications mentioned above. The study will monitor the levels of these medications in the blood and assess how the body processes them. This will help researchers learn more about the relationship between genetic factors and the treatment of breast and colon cancer with fluoropyrimidine medications.